Observational studyCancer medicine2019

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.

Young-Woo Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.